Infiltration of T Cells into a Three-Dimensional Psoriatic Skin Model Mimics Pathological Key Features.
Cell Differentiation
Cell Movement
Cell Proliferation
Dermis
/ immunology
Epithelium
/ drug effects
Female
Humans
Immunocompetence
Inflammation
/ pathology
Inflammation Mediators
/ metabolism
Keratinocytes
/ pathology
Lymphocyte Activation
/ immunology
Male
Methotrexate
/ pharmacology
Middle Aged
Models, Biological
Phenotype
Psoriasis
/ immunology
Signal Transduction
Skin
/ immunology
T-Lymphocytes
/ immunology
3D model
T cells
adaptive immunity
inflammation
psoriasis
tissue engineering
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 Apr 2019
03 Apr 2019
Historique:
received:
05
03
2019
revised:
29
03
2019
accepted:
01
04
2019
entrez:
17
4
2019
pubmed:
17
4
2019
medline:
31
7
2019
Statut:
epublish
Résumé
Psoriasis is an autoimmune chronic dermatosis that is T cell-mediated, characterized by epidermal thickening, aberrant epidermal differentiation and inflammatory infiltrates, with a dominant Th1 and Th17 profile. Additional in vitro models are required to study the complex interactions between activated T cells and skin cells, and to develop new, more effective treatments. We have therefore sought to model this psoriatic inflammation by the generation of tissue-engineered immunocompetent tissues, and we have investigated the response of activated T-cell infiltration in models produced with lesional psoriatic skin cells on major hallmarks of psoriasis. The immunocompetent lesional skin model displayed a delayed onset of epidermal differentiation, an hyperproliferation of the basal keratinocytes, a drastic increase in the secretion of proinflammatory cytokines, and a disturbed expression of key transcription factors, as observed in lesional plaques, suggesting a crucial importance of combining the pathological phenotype of cutaneous cells to T cells in order to generate a relevant model for psoriasis. Finally, we found this skin model to be responsive to methotrexate treatment, making it a valuable tool for drug development.
Identifiants
pubmed: 30987186
pii: ijms20071670
doi: 10.3390/ijms20071670
pmc: PMC6479293
pii:
doi:
Substances chimiques
Inflammation Mediators
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Canadian Institutes of Health Research
ID : MOP-311262
Pays : Canada
Références
J Am Acad Dermatol. 2003 Jun;48(6):829-35
pubmed: 12789171
J Invest Dermatol. 1992 Jul;99(1):27-34
pubmed: 1351505
J Invest Dermatol. 1992 Jun;98(6):902-10
pubmed: 1375620
J Dermatol Sci. 1992 Jul;4(1):18-25
pubmed: 1390454
N Engl J Med. 2003 Nov 20;349(21):2014-22
pubmed: 14627786
J Exp Med. 2004 Mar 1;199(5):731-6
pubmed: 14981113
Trends Immunol. 2004 Jun;25(6):295-305
pubmed: 15145319
J Dermatol. 2004 Apr;31(4):271-6
pubmed: 15187321
J Clin Invest. 2004 Jun;113(12):1664-75
pubmed: 15199399
Curr Opin Rheumatol. 2004 Jul;16(4):331-7
pubmed: 15201593
N Engl J Med. 2005 May 5;352(18):1899-912
pubmed: 15872205
J Exp Med. 2005 Jul 4;202(1):135-43
pubmed: 15998792
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S67-80
pubmed: 16488332
Br J Dermatol. 2006 Nov;155(5):876-82
pubmed: 17034513
Arch Dermatol Res. 1991;283(7):465-71
pubmed: 1724897
Clin Exp Immunol. 2007 Dec;150(3):407-15
pubmed: 17900301
J Invest Dermatol. 2008 May;128(5):1207-11
pubmed: 18200064
J Invest Dermatol. 2009 Jan;129(1):79-88
pubmed: 18633443
Am J Pathol. 2008 Sep;173(3):815-23
pubmed: 18669614
J Dermatol Sci. 2009 Jan;53(1):19-25
pubmed: 18783923
J Exp Med. 2009 Jan 16;206(1):249-58
pubmed: 19114666
Nat Med. 2009 Sep;15(9):1013-5
pubmed: 19684581
Arch Dermatol Res. 2010 Sep;302(7):499-505
pubmed: 20148256
Curr Opin Immunol. 2010 Apr;22(2):223-30
pubmed: 20207527
J Invest Dermatol. 2010 Oct;130(10):2412-22
pubmed: 20555352
Am J Pathol. 2010 Dec;177(6):3112-24
pubmed: 20971736
Tissue Eng Part A. 2011 Jul;17(13-14):1859-68
pubmed: 21417679
J Allergy Clin Immunol. 2011 Sep;128(3):574-82.e1-12
pubmed: 21704361
J Invest Dermatol. 2011 Dec;131(12):2401-8
pubmed: 21796151
J Dermatol Sci. 1990 Nov;1(6):441-6
pubmed: 2288899
Br J Dermatol. 2013 Feb;168(2):302-10
pubmed: 23013371
Curr Opin Immunol. 2013 Apr;25(2):214-21
pubmed: 23298609
J Invest Dermatol. 2013 Oct;133(10):2362-2371
pubmed: 23594598
J Invest Dermatol. 2014 Mar;134(3):719-727
pubmed: 24121402
J Immunol. 2014 Apr 1;192(7):3111-20
pubmed: 24610014
Nat Rev Immunol. 2014 Nov;14(11):768-74
pubmed: 25257362
Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8046-51
pubmed: 26080440
Eur J Immunol. 2015 Nov;45(11):3022-33
pubmed: 26332438
Regen Med. 2016 Sep;11(6):545-57
pubmed: 27513102
J Immunol. 1987 Jun 15;138(12):4114-20
pubmed: 2884260
JAMA. 1986 Dec 12;256(22):3110-6
pubmed: 3023712
Br J Dermatol. 1985 Jun;112(6):647-53
pubmed: 3890921
J Invest Dermatol. 1993 Nov;101(5):701-5
pubmed: 7693825
J Clin Invest. 1996 Oct 15;98(8):1878-87
pubmed: 8878440
Lancet. 1997 Aug 2;350(9074):349-53
pubmed: 9251649